TeamDrive
RUS
Maxim Chernin

Maxim Chernin

Partner

Телефоны:

+7 495 545-39-12

Send message

Maxim has joined to the "Team Drive" in October 2017.

Before that, he headed the Client’s Welfare Department of Sberbank as a Managing director. He was a board member of subsidiaries and played a key part in developing insurance, pension and investment activity of this biggest Russian bank. In 2010 as a CEO Maxim organized from scratch “Sberbank life insurance” project. Today it is recognized market leader in its field. Maxim’s professional record includes 10 years experience in insurer company Allianz (former ROSNO). He started as a specialist of marketing research department and in few years he became a member of the Management Board with a wide range of responsibilities. Companies and departments had been growing strongly under his guidance. His management was cost-effective, profitable for shareholders and provided high-quality services for the clients.

Now Maxim is a member of the Government Expert Council of the Russian Federation and of the Public Council under the Ministry of Health of the Russian Federation.

Since 2010 Maxim leads the committee of life insurance in the All-Russian Insurance Association (ARIA). He is also a member of the Board of the All-Russian Insurance Association and of the Association of Life Insurers. In addition, Maxim is a Board member of PJSC Rosgosstrakh insurance company.

In 2017, Maxim was awarded by the National Financial Award “Reputation” in the nomination “For Personal Merits in the Development of Insurance in Russia”. In 2016 he was included into the “Top 250 of the Russian principals” rating according to the estimation of “Kommersant” magazine. In 2014, Maxim was awarded the ARIA honorary medal "For Merits in the Development of Insurance in Russia". In 2011, the “Finance” magazine included Maxim in the annual list of the most successful young businessperson in Russia.

Maxim graduated with honours from the National Research University “Higher School of Economics” majoring in “Strategic Management”.

Media Center

  • 31 October 2018

    Scientists unveiled a more effective approach for assessing drug response

    Scientists from Eli Lilly and Company, the Icahn School of Medicine at Mount Sinai (New York, USA) and Sema4 (Stamford, USA) released results from a proof-of-concept study demonstrating that patient-derived cells offer a more effective approach for assessing drug response than conventional methods.

  • 30 October 2018

    Researchers developed an AI approach to identify antibiotic resistance genes

    Researchers at the University of California San Diego (USA) have developed an approach that uses machine learning to identify and predict which genes make infectious bacteria resistant to antibiotics. The approach was tested on strains of Mycobacterium tuberculosis – the bacteria that cause tuberculosis (TB) in humans. It identified 33 known and 24 new antibiotic resistance genes in these bacteria.

  • 29 October 2018

    Expanding the reach of gene editing with a new CRISPR enzyme

    The CRISPR-Cas9 gene editing system has been widely studied because of its potential therapeutic applications, but limitations in the number of locations on the genome it can target remain a major drawback. Now scientists at the Massachusetts Institute of Technology have identified a new Cas9 enzyme that they say can help CRISPR reach more gene mutations.

  • 26 October 2018

    Biotech Backed by Bain, Pfizer loads prime CNS assets into new biotech

    Pfizer has followed through on its pledge to divest a hunk of its neuroscience R&D, spinning several programs into a new company called Cerevel Therapeutics backed by $350 million in venture funding. Pfizer is contributing a trio of clinical-stage drug candidates—including a Parkinson’s therapy due to start phase 3 testing next year—plus a clutch of earlier-stage programs, while Bain Capital and affiliates stumped up the initial funding.

Read more